Direct Quantitation of Psilocybin and Psilocin by One-Dimensional 1H and 31P qNMR in a revived Greek specimen of Psilocybe cyanescens
Prokopios Magiatis, Evangelos Dadiotis, Romanos Konstantinos Antonopoulos, Kostas Ioannidis, Vangelis Mitsis, E Melliou, Zacharoula Gonou‐zagou
Planta Medica December 1, 2022 DOI: 10.1055/s-0042-1759062 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Prodrug Secondary metabolite Stereochemistry |
| Citations | 1 |
| Key findings | Psilocybin, a prodrug of psilocin produced by Psilocybe fungi, is being used in clinical trials for Major Depressive Disorder, existential distress in terminally ill patients, and Alcohol Use Disorder. |
Abstract
The genus Psilocybe of Basidiomycota includes more than two hundred species of mushroom-forming fungi, which are widely known for the production of the secondary metabolite psilocybin, a prodrug of its in vivo dephosphorylated active metabolite psilocin [1]. Psilocybin is being currently used in numerous clinical trials including the treatment of Major Depressive Disorder (MDD) [2], existential distress of terminally ill patients [3] and Alcohol Use Disorder (AUD) [4], creating the need of investigating and quantitating these substances.